---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060199"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:13:53.966712+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics reports Q1 2024 net loss of $13.8M; completes $40M private placement

## Summary
- Net loss of $13.8M for Q1 2024 vs $41.9M Q1 2023; decrease due to $29.6M IPR&D expense from Flame merger in prior year.
- Completed $40M private placement with Gilead and other investors; net proceeds $37.2M extend cash runway into Q2 2026.
- Expanded Part B of DeFianCe CRC study from 130 to 180 patients; enrollment expected late Q3/Q4 2024, data mid-2025.
- Part C of DisTinGuish GEJ/gastric cancer study fully enrolled (170 patients); initial data expected H2 2024 or early 2025.
- Cash and equivalents $54.9M at March 31, 2024; exclusive of April 2024 private placement proceeds.

## SEC filing metadata
- accession: 0001104659-24-060199
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465924060199/0001104659-24-060199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465924060199/tm2414104d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060199
- JSON: https://secwatch.observer/filing/0001104659-24-060199.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060199.txt

## Key facts
- Earnings Releases
  CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2024 results: net income $13.8 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $13.8 million
  - Result: reported results
  source text: Net Loss was $13.8 million for the first quarter 2024, compared to $41.9 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465924060199/0001104659-24-060199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.